Ignyta Raises Additional $1M Through Capital Term Loan from Silicon Valley Bank

By: Benzinga
Ignyta, the personalized medicine company dedicated to improving the diagnosis and treatment of patients with rheumatoid arthritis (RA), lupus and other autoimmune diseases, announced today that Silicon Valley Bank (SVB) has expanded its support of Ignyta through an additional $1M capital term loan facility. The new facility is incremental to
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.